Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia
Abstract Background This research aimed to determine the cost-effectiveness of nephroprotection programs compared to no intervention in adults with type 2 diabetes mellitus (T2DM) in the Colombian national health system. Methods A Markov analysis with 3 disease states (controlled, uncontrolled and d...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12962-025-00618-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726151743766528 |
|---|---|
| author | Cristian Alejandro González-Rojas Sergio Augusto Cáceres-Maldonado Luis Alberto Soler-Vanoy Lizbeth Alexandra Acuña-Merchán |
| author_facet | Cristian Alejandro González-Rojas Sergio Augusto Cáceres-Maldonado Luis Alberto Soler-Vanoy Lizbeth Alexandra Acuña-Merchán |
| author_sort | Cristian Alejandro González-Rojas |
| collection | DOAJ |
| description | Abstract Background This research aimed to determine the cost-effectiveness of nephroprotection programs compared to no intervention in adults with type 2 diabetes mellitus (T2DM) in the Colombian national health system. Methods A Markov analysis with 3 disease states (controlled, uncontrolled and death) was modeled using a 1-year cycle and a 10-year time horizon based on T2DM and chronic kidney disease (CKD) data in Colombia from 2020 to 2023 from the perspective of the health insurance system. Effectiveness was considered as the control of CKD progression, with a decrease of estimated glomerular filtration rate (eGFR using CKD-EPI) of less than 5 ml/min/1.73 m2, and glycated hemoglobin (HBA1c) of less than or equal to 7%. Costs are expressed in 2023 $USD. Univariate and multivariate probabilistic sensitivity analyses were conducted using 1,000 Monte Carlo simulations. Results Compared to no intervention, nephroprotection programs were found to be cost-effective, with a dominant incremental cost-effectiveness ratio (ICER). Furthermore, the sensitivity analysis results showed that having a nephroprotection program is a cost-effective strategy in 89.2% and dominant in 56.7% of the simulations. Conclusions Nephroprotection programs result in better T2DM control and slower CKD progression, while also being lower in costs incurred during the year. |
| format | Article |
| id | doaj-art-2b51b8c19f034637b53788bc1e968625 |
| institution | DOAJ |
| issn | 1478-7547 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cost Effectiveness and Resource Allocation |
| spelling | doaj-art-2b51b8c19f034637b53788bc1e9686252025-08-20T03:10:17ZengBMCCost Effectiveness and Resource Allocation1478-75472025-04-0123111210.1186/s12962-025-00618-8Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in ColombiaCristian Alejandro González-Rojas0Sergio Augusto Cáceres-Maldonado1Luis Alberto Soler-Vanoy2Lizbeth Alexandra Acuña-Merchán3Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto CostoCuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto CostoCuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto CostoCuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto CostoAbstract Background This research aimed to determine the cost-effectiveness of nephroprotection programs compared to no intervention in adults with type 2 diabetes mellitus (T2DM) in the Colombian national health system. Methods A Markov analysis with 3 disease states (controlled, uncontrolled and death) was modeled using a 1-year cycle and a 10-year time horizon based on T2DM and chronic kidney disease (CKD) data in Colombia from 2020 to 2023 from the perspective of the health insurance system. Effectiveness was considered as the control of CKD progression, with a decrease of estimated glomerular filtration rate (eGFR using CKD-EPI) of less than 5 ml/min/1.73 m2, and glycated hemoglobin (HBA1c) of less than or equal to 7%. Costs are expressed in 2023 $USD. Univariate and multivariate probabilistic sensitivity analyses were conducted using 1,000 Monte Carlo simulations. Results Compared to no intervention, nephroprotection programs were found to be cost-effective, with a dominant incremental cost-effectiveness ratio (ICER). Furthermore, the sensitivity analysis results showed that having a nephroprotection program is a cost-effective strategy in 89.2% and dominant in 56.7% of the simulations. Conclusions Nephroprotection programs result in better T2DM control and slower CKD progression, while also being lower in costs incurred during the year.https://doi.org/10.1186/s12962-025-00618-8Cost-effectiveness analysisType 2 diabetesChronic kidney diseaseNephroprotection programs |
| spellingShingle | Cristian Alejandro González-Rojas Sergio Augusto Cáceres-Maldonado Luis Alberto Soler-Vanoy Lizbeth Alexandra Acuña-Merchán Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia Cost Effectiveness and Resource Allocation Cost-effectiveness analysis Type 2 diabetes Chronic kidney disease Nephroprotection programs |
| title | Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia |
| title_full | Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia |
| title_fullStr | Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia |
| title_full_unstemmed | Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia |
| title_short | Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia |
| title_sort | cost effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in colombia |
| topic | Cost-effectiveness analysis Type 2 diabetes Chronic kidney disease Nephroprotection programs |
| url | https://doi.org/10.1186/s12962-025-00618-8 |
| work_keys_str_mv | AT cristianalejandrogonzalezrojas costeffectivenessanalysisofnephroprotectionprogramsforpatientswithtype2diabetesmellitusininsurersincolombia AT sergioaugustocaceresmaldonado costeffectivenessanalysisofnephroprotectionprogramsforpatientswithtype2diabetesmellitusininsurersincolombia AT luisalbertosolervanoy costeffectivenessanalysisofnephroprotectionprogramsforpatientswithtype2diabetesmellitusininsurersincolombia AT lizbethalexandraacunamerchan costeffectivenessanalysisofnephroprotectionprogramsforpatientswithtype2diabetesmellitusininsurersincolombia |